Yaping Zhou, Yitan Zou, Shaodong Lv, Dan Tan, Guangyao Li, Wenyan Fu, Changhai Lei, Mingdong Lu, Shi Hu. Antibody screening for tumor and immune hotspot targets: the frontier of new methods and technologies[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2025.101417
Citation:
Yaping Zhou, Yitan Zou, Shaodong Lv, Dan Tan, Guangyao Li, Wenyan Fu, Changhai Lei, Mingdong Lu, Shi Hu. Antibody screening for tumor and immune hotspot targets: the frontier of new methods and technologies[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2025.101417
Yaping Zhou, Yitan Zou, Shaodong Lv, Dan Tan, Guangyao Li, Wenyan Fu, Changhai Lei, Mingdong Lu, Shi Hu. Antibody screening for tumor and immune hotspot targets: the frontier of new methods and technologies[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2025.101417
Citation:
Yaping Zhou, Yitan Zou, Shaodong Lv, Dan Tan, Guangyao Li, Wenyan Fu, Changhai Lei, Mingdong Lu, Shi Hu. Antibody screening for tumor and immune hotspot targets: the frontier of new methods and technologies[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2025.101417
a. Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325003, Zhejiang Province, China;
b. Department of Biomedical Engineering, College of Basic Medical Sciences, Naval Medical University (Second Military Medical University), Shanghai 200433, China;
c. Department of Biophysics, College of Basic Medical Sciences, Naval Medical University (Second Military Medical University), Shanghai 200433, China;
d. Department of Respiratory and Critical Care Medicine, Shanghai Changhai Hospital, Second Military Medical University, Shanghai 200433, China;
e. Hepatic Surgery Department V, The Third Affiliated Hospital of Naval Medical University, Shanghai 200433, China;
f. Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China
Advancements in tumor immunotherapy highlight the significant potential of antibody drugs, a key category of biological agents, for treating cancer and autoimmune diseases. This paper begins by defining and classifying key targets in tumor immunity, as well as discussing their structural and functional characteristics. Subsequently, it elaborates on innovative technologies for antibody drug screening, which, when integrated with contemporary molecular biology, biotechnology, and computational biology, have substantially enhanced the efficiency and accuracy of target identification and antibody drug screening processes. Despite the promising prospects of tumor immunotherapy, certain limitations persist in its practical implementation. In conclusion, this paper offers a comprehensive examination of the cutting-edge developments in tumor immunotherapy, focusing on the aspects of tumor immunotherapy itself, critical targets for immunotherapy, and novel technologies and methodologies for antibody screening. This analysis is crucial for advancing the field of tumor immunotherapy and for enhancing both therapeutic efficacy and safety. Furthermore, research and development of antibody drugs in other domains, such as autoimmune and inflammatory diseases, can benefit from it.